

June 24, 2010

To Whom It May Concern:

I am a Physician Assistant working in ENT Allergy. I see a large number of Medicaid patients, many of who benefit greatly from Nasonex or Singulair, or both.

Nasonex is a well-tolerated steroidal nasal spray that is very helpful in the treatment of both allergic and non-allergic rhinitis. Keeping Nasonex on the Medicaid formulary would benefit many of my patients, by keeping options open for use of steroid nasal sprays. Many patients have tried several different steroid nose sprays and find that only one type works well for them. In many cases, that one is Nasonex. Steroid nose sprays are a safe and effective preventative treatment for allergies.

Singulair, likewise, benefits many of my Medicaid patients. It is helpful in the treatment of well controlled asthma and also helps allergy symptoms. Since it is beneficial in treating two disease processes, I feel it is a wise choice to keep it on the Medicaid formulary.

Thank you for your consideration of keeping Nasonex and Singulair on the Medicaid formulary.

Sincerely,

Kara E. McGee, PA-C Allergy Clinic Idaho



John D. Jeppson, M.D. Michael V. Keiley, M.D. G. William Palmer, M.D. Heidi Peters, FNP Physicians are Diplomats of the American Board of Allergy and Immunology

June 18th, 2010

Robert Faller Pharmacy & Therapeutics Committee 3232 Elder St. Boise, ID 83705

Dear Robert:

I understand that it is that time of year again. As an allergist treating children, it is nice to have therapeutic options and my understanding is that Patanase is being reviewed. It has a new pediatric indication, which I think is helpful and also the side effect profile is very favorable. It does have less of an irritating taste, which may aid in compliance in using that. Patanase and Astepro I think are both good products and should be available for patients that need them. In addition, all the eyedrops that we use and of course the Patanol and Pataday products have been very well received and I would be hopeful that they could be covered under Medicaid as well. Please feel free to contact me if you have any questions or concerns.

Sincerely,

JOHN D. JEPPSON, M.D. () (Adult & Pediatric Allergy & Astrima

JDJ/slj



215 E. Hawaii Ave. • Nampa, Idaho 83686 • (208) 463-3000

June 17, 2010

Mr. Robert Faller
Pharmacy & Therapeutics Committee
3232 Elder Street
Boise, Idaho 83705

Dear Mr. Faller,

I am writing in hopes that you will consider the addition of Patanase Nasal Spray to the preferred Medicaid drug list.

I have witnessed excellent medical benefit in regards to allergy control, as well as reducing secondary sinus and ear infections. I have had improved compliance with this medication as compared to other nasal antihistamines that are currently on the list. This is the only nasal antihistamine that is indicated down to the age of 6.

I believe this medication is very effective in treating early onset of this media, and may play a role in prevention of surgical intervention for chronic middle ear infections.

Thank you for your consideration of my request to add Patanase Nasal Spray to the Medicaid formulary as a preferred agent. If I can be of any further assistance, please feel free to contact me.

Sincerely,

Thomas F. Douthit, PA-C

Saltzer Medical Group

Otolaryngology Department

Theoretical Control of the Control o

Don Beasley, M.D., F.A.C.S. Address a State Programming and a programming of the state of the st

TFD/sd

Consequence of a green consequence of the position of the first of the consequence of the second of the second of the consequence of



John D. Jeppson, M.D. Michael V. Keiley, M.D. G. William Palmer, M.D. Heidi Peters, FNP

June 1st, 2010

Tammy Eide Farm V, VCP Medicaid Pharmacy Program Supervisor

Idaho Department of Health and Welfare 3232 Elder St. Boise, ID 83705

Dear Tammy:

I was informed that QVAR is up for Medicaid review and just wanted to write you a quick in support of continuing to have QVAR on the formulary. Historically QVAR has been one of our less expensive inhaled steroids, but in addition to that advantage, the Beclomethasone molecule is soluble in the HFA propellant so that the particle size is very small and potentially can have deposition in the smallest of airways. While it is really good to have choices in inhaled steroids, this one does have that particular characteristic that I think makes it of benefit. Some patients will even use it in conjunction with a different inhaled steroid with larger particle sizes so I would really support strongly its remaining on formulary. Please feel free to contact me if you have any other questions or concerns.

Sincerely,


JOHN D. JEPPSON, M.D. Adult & Pediatric Allergy & Asthma

JDJ/slj

Physicians are Diplomats of the

American Board of Allergy

and Immunology



Gregory M. Wickern, M.D.

800 Falls Avenue, Suite 2 Twin Falls, Idaho 83301 (208) 734-6091 FAX (208) 734-4654

June 8, 2010

Ms. Tami Eide, Supervisor Pharm D Medicaid Pharmacy IDAHO DEPT HEALTH & WELFARE 3232 Elder Street Boise ID 83705

Dear Tami:

We have been notified that Qvar is up for review in July. We use a considerable about of Qvar for children with significant asthma as well as for rhinitis.

We recommend maintaining Qvar-40 and Qvar-80 on the formulary.

Thank you for your time and help with this request. We remain,

Cordially,

Gregory J. Kadlec, M. D.

GJK/jh

Richard E. Henry, M. D.

REH/jh

Copy: Tom Mulroy, TEVA